TT-034
Phase 1- Indications
- Hepatitis C
Company intelligence / Profile preview
Tacere Therapeutics
San Jose, California, United Statesprnewswire.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
The company has a drug candidate BB-201 in preclinical stage for Wet Macular Degeneration and TT-034 (pending status) for Pseudohyperkalemia Cardiff. TT-034 contains three separate RNAi elements targeted against the Hepatitis C virus.
- Therapeutic areas
- OphthalmologyHematologyInfectious Diseases
- Modalities
- RNA interference (RNAi)AAV based gene therapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Beyond the preview
Go deeper on Tacere Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tacere Therapeutics.